OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
84 hedge funds and large institutions have $141M invested in OncoMed Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 8 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 15
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
32% more capital invested
Capital invested by funds: $107M → $141M (+$33.9M)
30% more call options, than puts
Call options by funds: $790K | Put options by funds: $608K
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
1% more funds holding
Funds holding: 83 → 84 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.64M |
| 2 |
IHM
Iguana Healthcare Management
New York
|
+$2M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.38M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.3M |
| 5 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$1.3M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.13M |
| 3 |
Jennison Associates
New York
|
-$905K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$832K |
| 5 |
JP Morgan Chase
New York
|
-$463K |
OMED Hedge Fund Activity: Q2 2016 in Review
84 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2016, worth a combined $141M — up 32% from $107M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OMED positions and 8 closed out — a net gain of 1 holder — while 34 added to existing stakes and 15 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.64M. The largest seller was First Eagle Investment Management, cutting an estimated $1.3M.
- 84 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2016, up from 83 in Q1 2016.
- Funds reported $141M of OncoMed Pharmaceuticals, Inc. stock for Q2 2016, up 32% quarter-over-quarter.
- 9 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2016 and 8 closed out, a net change of +1 holder.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q2 2016 was Millennium Management, an estimated $4.64M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2016 was First Eagle Investment Management, an estimated $1.3M sold.
Based on aggregated 13F filings for Q2 2016.